𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antibody avidity following varicella-zoster virus infections

✍ Scribed by Dr. Hillar O. Kangro; Shazad Manzoor; David R. Harper


Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
884 KB
Volume
33
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


The avidity of IgG antibodies following varicella-zoster virus (VZV) infections was investigated using urea treatment of antigen-bound serum antibody by indirect radioimmunoassay (RIA) and immunoblotting techniques. Sequential sera from 16 patients with varicella and 17 patients with zoster were tested, as well as sera from 80 seropositive individuals without a recent history of VZV disease. Both types of assay showed that low-avidity antibodies predominate early after primary infection, but that antibody avidity increases markedly during convalescence. Using RIA, all sera taken up to 12 weeks after the onset of varicella showed greater than 50% reduction in antibody titre after treatment with 8 M urea but thereafter the proportion of urea resistant antibody increased with time. In contrast, after recurrent infection, high avidity antibodies were found to predominate at all times. Only 6 of 47 sera tested from zoster cases showed greater than 30% reduction after urea treatment and all these were taken within 2 weeks after onset of rash. Immunoblotting also showed that the highly immunogenic p32/p36 nucleoproteins appear to induce predominantly low avidity antibodies, even after recurrent VZV infection. The results of this study indicate that treatment with 8 M urea in RIA for IgG antibodies may be a simple and reliable method for distinguishing primary and anamnestic antibody responses against VZV.


πŸ“œ SIMILAR VOLUMES


Current management of varicella zoster v
✍ Prof. H. H. Balfour Jr. πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 955 KB

A series of randomized, placebo-controlled, double-blind clinical trials conducted from 1980 to the present provide the basis for appropriate management of varicella-zoster virus (VZV) infections. Placebo recipients in these studies have also provided valuable natural history data on the clinical co

Varicella-zoster virus antibody avidity
✍ Dr. Anne K. Junker; Peter Tilley πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 637 KB

## Abstract The normal immune response after primary varicella‐zoster virus (VZV) infection includes IgG subclass evolution to predominantly IgG1‐type antibodies, and maturation from low to high avidity antibodies which are maintained for life. Twenty‐three healthy and apparently immuno‐competent c

Varicella-zoster virus infection in immu
✍ Dr. T. Masaoka; A. Hiraoka; H. Teshima; N. Tominaga πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 214 KB

The prophylactic effect of acyclovir (ACV) on varicella-zoster virus (VZV) infection in leukaemia patients who have undergone bone marrow transplantation (BMT) was reviewed. The benefits of the use of the laminar air flow (LAF) room in the prevention of nosocomial VZV infections in the haematologica

Antibodies against varicella-zoster viru
✍ C. F. R. KΓ€llander; E. G. Torfason; H. Diderholm; J. S. Gronowitz; E. Olding-Ste πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 707 KB

Antibody responses to varicella-zoster virus (VZV) deoxythymidine kinase (dTK) and herpes simplex virus (HSV) dTK in homologous and heterologous infections were studied. Antibodies blocking the enzymatic activity of VZV-dTK appeared late after varicella and decreased more or less in parallel with th

Neutralizing antibody responses induced
✍ Haumont, M.; Jurdan, M.; Kangro, H.; Jacquet, A.; Massaer, M.; Deleersnyder, V.; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 41 KB

The purpose of this study was to compare the antibody responses to varicella-zoster virus (VZV) gE and gB after natural VZV infection and after vaccination with live attenuated OKA vaccine in order to determine the relative importance of these proteins as components of a subunit vaccine. Anti-VZV an